바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

568누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

ADCBiologicEnyo PharmaPhase 2

B-CAP (B-CAP)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+3

효능 ORR 0.04%임상시험 61상태 ACTIVE

CGTBiologicAbbottvedotinPhase 2

Zidovudine (Zidovudine)

Lymphoproliferative Disorder; HHV-8 · Adult T-cell Leukemia-Lymphoma

#AdultT-cellLeukemia-Lymphoma#CGT#Phase2#인기#세포유전치료+5

임상시험 60상태 RECRUITING

AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, ipilimumab + nivolumab)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+4

효능 ORR 77.8%임상시험 60상태 RECRUITING

CGTBiologicTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5

임상시험 60상태 RECRUITING

CGTBiologicNational Heart, Lung, and Blood…Phase 2

Haploidentical Hematopoietic Cell Transplantation (Haploidentical Hematopoietic Cell Transplantation)

Hemoglobinopathy (Disorder); Severe Aplastic Anemia · Primary Immune Deficiency Disorders

#PrimaryImmuneDeficiencyDisorders#CGT#Phase2#인기#세포유전치료+5

임상시험 60상태 RECRUITING

CGTBiologicSabz BiomedicalsPhase 2

cytokine-induced killer cell (cytokine-induced killer cell)

Colon Cancer Stage IV · Solid Tumors

#SolidTumors#CGT#Phase2#인기#세포유전치료+5

임상시험 60상태 ACTIVE

CGTBiologicTurnstone Biologics, Corp.Phase 1

RT-01 (Oncolytic Virus Injection, Oncolytic Virus Injection(RT-01))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#CGT#Phase1#인기#세포유전치료+4

효능 ORR 28%임상시험 60상태 ACTIVE

AntibodyRocheDM1) and trastuzumab deruxt…Preclinical

trastuzumab (Herceptin, Trastuzumab + Pertuzumab)

Solid Tumor; Advanced Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Preclinical#인기#항체+5

효능 ORR 79.5%임상시험 60상태 RECRUITING

ADCBiologicMerck Sharp & Dohme LLCPhase 1

Gemcitabine/Cisplatin II (Gemcitabine/Cisplatin II)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#인기#항체약물접합체+2

효능 ORR 72%임상시험 60상태 ACTIVE

CGTBiologicMedigene AGPhase 2

Lymphodepletion (Lymphodepletion)

Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer · FRα

#FR#CGT#Phase2#인기#세포유전치료+5

효능 0%임상시험 60상태 DISCONTINUED

CGTBiologicLion TCR Pte. Ltd.Phase 1

TCR-T (TCR-T)

Chronic Hepatitis B · Chronic Hepatitis B

#ChronicHepatitisB#CGT#Phase1#인기#세포유전치료+4

효능 ORR 50%임상시험 60상태 ACTIVE

ADCBiologicOnconic Therapeutics Inc.releasePhase 2

PARP inhibitor (PARP inhibitor)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 27.66%임상시험 60상태 RECRUITING

CGTBiologicEpicentRx, Inc.Phase 2

Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune)

Solid Tumor, Adult; Cancer · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase2#인기#세포유전치료+5

효능 ORR 59%임상시험 60상태 RECRUITING

CGTBiologicSinobioway Cell Therapy Co., Lt…Preclinical

CD19-targeted CAR-T cells (CD19-targeted CAR-T cells)

Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5

효능 ORR 94%임상시험 60상태 ACTIVE

AntibodyJanssenApproved

Teclistamab (Teclistamab)

Myeloma Multiple; Plasma Cell Leukemia · Myeloma Multiple

#MyelomaMultiple#Antibody#Approved#인기#항체+5

임상시험 60상태 RECRUITING

ADCBiologicGruppo Oncologico del Nord-OvestPhase 3

l-leucovorin (l-leucovorin)

Metastatic Colorectal Cancer · Gastric Cancer

#GastricCancer#ADC#Phase3#인기#항체약물접합체+3

효능 ORR 36.6%임상시험 60상태 ACTIVE

AntibodyGlaxoSmithKlinederuxtecan improved objecti…Phase 2

Dostarlimab (Dostarlimab)

Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase2#인기#항체+5

효능 ORR 88%임상시험 60상태 DISCONTINUED

CGTBiologicTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5

임상시험 60상태 RECRUITING

ADCBiologicCanadian Cancer Trials Groupderuxtecan (T-DXd) showed a…Phase 2

darolutamide (darolutamide)

Prostate Cancer · Genitourinary Cancers

#GenitourinaryCancers#ADC#Phase2#인기#항체약물접합체+4

임상시험 60상태 RECRUITING

AntibodyRochegovitecan in patients with …Preclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#인기#항체+4

효능 ORR 46.4%임상시험 60상태 ACTIVE

AntibodyMario Negri Institute for Pharm…Approved

Certolizumab pegol (Certolizumab pegol)

Rheumatoid Arthritis · Crohn's Disease

#CrohnsDisease#Antibody#Approved#인기#항체+4

효능 ORR 5%임상시험 60상태 ACTIVE

CGTBiologicBellicum PharmaceuticalssPhase 2

Chimeric antigen receptor (CAR, Chimeric antigen receptor, Chimeric antigen receptor (CAR) T-cell therapy)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Phase2#인기#세포유전치료+4

효능 ORR 80.3%임상시험 60상태 RECRUITING

ADCBiologicQilu Pharmaceutical Co., Ltd.Phase 2

QL1706 (QL1706)

TNBC, Triple Negative Breast Cancer · Recurrent Cervical Cancer

#RecurrentCervicalCancer#ADC#Phase2#인기#항체약물접합체+5

임상시험 60상태 RECRUITING

CGTBiologicAmerican Gene Technologies Inte…sPreclinical

Gene modified therapy (Gene modified therapy)

HIV · HIV

#HIV#CGT#Preclinical#인기#세포유전치료+4

효능 ORR 41.6%임상시험 60상태 ACTIVE

CGTBiologicGamma Medica-IdeasPhase 2

tamoxifen citrate (tamoxifen citrate)

Male Breast Cancer; Stage II Breast Cancer · Breast Cancer

#BreastCancer#CGT#Phase2#인기#세포유전치료+5

효능 ORR 13%임상시험 60상태 ACTIVE

12 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 568

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

B-CAP (B-CAP)

Zidovudine (Zidovudine)

nivolumab (Opdivo, ipilimumab + nivolumab)

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Haploidentical Hematopoietic Cell Transplantation (Haploidentical Hematopoietic Cell Transplantation)

cytokine-induced killer cell (cytokine-induced killer cell)

RT-01 (Oncolytic Virus Injection, Oncolytic Virus Injection(RT-01))

trastuzumab (Herceptin, Trastuzumab + Pertuzumab)

Gemcitabine/Cisplatin II (Gemcitabine/Cisplatin II)

Lymphodepletion (Lymphodepletion)

TCR-T (TCR-T)

PARP inhibitor (PARP inhibitor)

Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune)

CD19-targeted CAR-T cells (CD19-targeted CAR-T cells)

Teclistamab (Teclistamab)

l-leucovorin (l-leucovorin)

Dostarlimab (Dostarlimab)

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

darolutamide (darolutamide)

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Certolizumab pegol (Certolizumab pegol)

Chimeric antigen receptor (CAR, Chimeric antigen receptor, Chimeric antigen receptor (CAR) T-cell therapy)

QL1706 (QL1706)

Gene modified therapy (Gene modified therapy)

tamoxifen citrate (tamoxifen citrate)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

B-CAP (B-CAP)

Zidovudine (Zidovudine)

nivolumab (Opdivo, ipilimumab + nivolumab)

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Haploidentical Hematopoietic Cell Transplantation (Haploidentical Hematopoietic Cell Transplantation)

cytokine-induced killer cell (cytokine-induced killer cell)

RT-01 (Oncolytic Virus Injection, Oncolytic Virus Injection(RT-01))

trastuzumab (Herceptin, Trastuzumab + Pertuzumab)

Gemcitabine/Cisplatin II (Gemcitabine/Cisplatin II)

Lymphodepletion (Lymphodepletion)

TCR-T (TCR-T)

PARP inhibitor (PARP inhibitor)

Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune)

CD19-targeted CAR-T cells (CD19-targeted CAR-T cells)

Teclistamab (Teclistamab)

l-leucovorin (l-leucovorin)

Dostarlimab (Dostarlimab)

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

darolutamide (darolutamide)

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Certolizumab pegol (Certolizumab pegol)

Chimeric antigen receptor (CAR, Chimeric antigen receptor, Chimeric antigen receptor (CAR) T-cell therapy)

QL1706 (QL1706)

Gene modified therapy (Gene modified therapy)

tamoxifen citrate (tamoxifen citrate)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

B-CAP (B-CAP)

Zidovudine (Zidovudine)

nivolumab (Opdivo, ipilimumab + nivolumab)

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Haploidentical Hematopoietic Cell Transplantation (Haploidentical Hematopoietic Cell Transplantation)

cytokine-induced killer cell (cytokine-induced killer cell)

RT-01 (Oncolytic Virus Injection, Oncolytic Virus Injection(RT-01))

trastuzumab (Herceptin, Trastuzumab + Pertuzumab)

Gemcitabine/Cisplatin II (Gemcitabine/Cisplatin II)

Lymphodepletion (Lymphodepletion)

TCR-T (TCR-T)

PARP inhibitor (PARP inhibitor)

Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune)

CD19-targeted CAR-T cells (CD19-targeted CAR-T cells)

Teclistamab (Teclistamab)

l-leucovorin (l-leucovorin)